Therapeutic BCG Vaccines Global Market Report 2024

The therapeutic bcg vaccines market size has grown strongly in recent years. It will grow from $53.99 billion in 2023 to $57.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be attributed to several factors, including government initiatives aimed at tuberculosis (TB) control, strategies involving immune system modulation, global immunization programs to combat TB, utilization of therapeutic BCG for bladder cancer treatment, increased investments in vaccine manufacturing, and the emergence of drug-resistant strains of tuberculosis, which heightened the urgency for improved solutions and treatments.

The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $72.54 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. Anticipated growth in the forecast period can be linked to several factors, including the expansion of therapeutic BCG vaccines to address other medical indications, intensified research focused on immunotherapy, worldwide efforts aimed at combating emerging infectious diseases, supportive regulatory measures facilitating vaccine development, and a dedicated emphasis on tuberculosis elimination initiatives. Key trends expected in this period encompass advancements in vaccine technology, optimization of supply chains, industry consolidation through partnerships, heightened emphasis on patient education and awareness, exploration of alternative vaccine delivery methods, and the exploration of personalized medicine approaches in vaccination strategies.

The increasing global prevalence of tuberculosis (TB) is anticipated to propel the growth of the therapeutic BCG vaccine market in the foreseeable future. Tuberculosis is an infectious disease with potentially severe consequences, primarily affecting the lungs. The transmission of tuberculosis occurs through the inhalation of small droplets containing bacteria, often expelled into the air through coughing or sneezing. BCG vaccines are designed to stimulate the immune system to combat infection without causing active TB, providing consistent protection against severe forms of the disease, including adolescent TB meningitis. The therapeutic use of BCG vaccines has witnessed a surge due to the rising incidence of tuberculosis cases worldwide. In October 2022, the World Health Organization reported an estimated 10.6 million new TB cases in 2021, marking a 4.5% increase from the previous year, with 1.6 million deaths, including 187,000 among HIV-positive individuals. Consequently, the escalating global tuberculosis cases are a significant driver for the growth of the therapeutic BCG vaccine market.

The increasing prevalence of drug-resistant tuberculosis (DR-TB) cases is poised to drive the expansion of the therapeutic BCG vaccine market in the coming years. Drug-resistant TB occurs when Mycobacterium tuberculosis, the causative bacteria, develops resistance to standard medications used for treatment. While therapeutic Bacillus Calmette-Guérin (BCG) vaccines are primarily recognized for preventing specific forms of TB, their potential application in addressing drug-resistant tuberculosis has gained attention. For example, as of November 2023, the Centers for Disease Control and Prevention reported that 8.4% of TB cases in the United States in 2022 exhibited resistance to at least isoniazid, including 1.4% with multidrug resistance. Within the U.S.-born population, 5.7% had isoniazid-resistant TB, with 0.7% classified as multidrug-resistant TB. The increasing incidence of drug-resistant TB cases is thus a key factor driving the therapeutic BCG vaccine market.

Strategic partnerships have become a prominent trend in the therapeutic BCG vaccine market as major companies prioritize collaboration to bolster their market standing. Notably, in July 2021, Zendal, a Spain-based pharmaceutical company, forged a partnership with IAVI, a US-based not-for-profit organization, to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials. MTBVAC, the only live, attenuated Mycobacterium tuberculosis vaccine in development, aims to prevent tuberculosis in adults and adolescents who lack effective vaccination options. Additionally, it is positioned as a potentially more potent and durable vaccine than BCG for infants. This strategic collaboration aligns with the broader trend of rapid vaccine development, particularly evident in the context of the COVID-19 pandemic.

Major players in the therapeutic BCG vaccine market are directing their efforts towards vaccine innovation for diverse therapeutic applications, such as BCG immunotherapy, to broaden their customer base and address expanding patient needs. BCG immunotherapy involves utilizing the BCG vaccine for immunotherapeutic purposes, particularly in treating certain types of cancer, such as bladder cancer. In a noteworthy development in July 2023, The Serum Institute of India, a biotechnology and biopharmaceuticals company, received government approval to export its BCG vaccine to Canada for immunotherapeutic use in bladder cancer treatment. This live freeze-dried preparation, derived from an attenuated strain of Mycobacterium bovis (Bacillus Calmette-Guérin), is administered intravenously in 40 mg and 80 mg presentations. The targeted administration directly into the bladder aims to impact cancer cells effectively while minimizing effects on other parts of the body, exemplifying the industry's focus on therapeutic innovation and strategic collaborations.

In February 2022, Sanofi S.A., a France-based multinational pharmaceutical and healthcare corporation, acquired Amunix for an undisclosed sum. This strategic acquisition grants Sanofi access to Amunix's innovative Pro-XTEN, XPAT, and XPAC technologies, facilitating the delivery of conditionally activated biologics representing the next phase in biopharmaceutical innovation. These technological advancements are expected to bolster Sanofi's efforts in advancing and diversifying its portfolio of advanced therapies, particularly in the field of oncology. With approximately 20 compounds currently in the developmental pipeline, this acquisition aligns seamlessly with Sanofi's existing research and development initiatives. Amunix, headquartered in the United States, specializes in immuno-oncology and is dedicated to the discovery, design, and development of novel biologics, proteins, and peptide therapeutics.

Major companies operating in the therapeutic bcg vaccines market report are Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., PowderJect Pharmaceuticals, Microgen, Taj Pharma Ltd., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, China Biotechnology Co Ltd., GlaxoSmithKline plc, Pfizer Inc., Bharat Biotech International Ltd., Biological E. Limited, Shanghai Institute of Biological Products Co. Ltd., Immunitor, Vakzine Projekt Management GmbH, Cipla Limited, Instituto Butantan, Chiron Corporation.

Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2023. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic bcg vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

There are two primary types of therapeutic BCG vaccines such as therapy BCG and immune BCG. Therapy BCG is an intravesical immunotherapy specifically targeting early-stage bladder cancer by bolstering the immune system to target and eliminate cancer cells. This vaccine can be administered to both pediatric and adult populations and finds applications in hospitals, clinics, and various other healthcare settings.

The therapeutic BCG vaccines market research report is one of a series of new reports that provides therapeutic BCG vaccines market statistics, including therapeutic BCG vaccines industry global market size, regional shares, competitors with a therapeutic BCG vaccines market share, detailed therapeutic BCG vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic BCG vaccines industry. This therapeutic BCG vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.